ADC Therapeutics (ADCT) Total Debt (2020 - 2026)

ADC Therapeutics has disclosed Total Debt across 7 years of filings, most recently posting $115.7 million for Q1 2026.

• Total Debt for Q1 2026 came in at $115.7 million, up 1.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.7 million (up 1.65% YoY), and the FY2025 annual result was $115.5 million, up 1.6% from the prior year.
• Total Debt came in at $115.7 million for Q1 2026 at ADC Therapeutics, roughly flat from $115.5 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $115.7 million in Q1 2026 to a low of $109.7 million in Q4 2022.
• The 5-year median for Total Debt is $113.8 million (2025), against an average of $113.8 million.
• Across the five-year window, Total Debt advanced 25.89% in 2022 and grew 0.53% in 2025, its largest moves.
• ADC Therapeutics' Total Debt stood at $109.7 million in 2022, then advanced by 2.72% to $112.7 million in 2023, then gained by 0.83% to $113.6 million in 2024, then climbed by 1.6% to $115.5 million in 2025, then increased by 0.19% to $115.7 million in 2026.
• The last three Total Debt figures came in at $115.7 million (Q1 2026), $115.5 million (Q4 2025), and $115.2 million (Q3 2025), per Business Quant data.